These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17675455)

  • 1. Absence of a pharmacokinetic interaction between entecavir and adefovir.
    Bifano M; Yan JH; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2007 Oct; 47(10):1327-34. PubMed ID: 17675455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
    Zhou XJ; Fielman BA; Lloyd DM; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2309-15. PubMed ID: 16801406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers.
    Fok BS; Gardner S; Piscitelli S; Chen S; Chu TT; Chan JC; Tomlinson B
    Clin Ther; 2013 Jan; 35(1):68-76. PubMed ID: 23274144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
    Sokal EM; Kelly D; Wirth S; Mizerski J; Dhawan A; Frederick D
    J Clin Pharmacol; 2008 Apr; 48(4):512-7. PubMed ID: 18276803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers.
    Huang J; Zhang Y; Huang X; Li L; Li Y; Wang K; Yang J; He Y; Lv Y; Zheng Q
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):8-14. PubMed ID: 24219967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers.
    Zhang QH; Yang J; He Y; Liu F; Wang JP; Davey AK
    Arzneimittelforschung; 2010; 60(10):640-4. PubMed ID: 21125816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
    Kearney BP; Ramanathan S; Cheng AK; Ebrahimi R; Shah J
    J Clin Pharmacol; 2005 Aug; 45(8):935-40. PubMed ID: 16027404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
    Gish RG; Clark MD; Kane SD; Shaw RE; Mangahas MF; Baqai S
    Clin Gastroenterol Hepatol; 2012 Aug; 10(8):941-6; quiz e68. PubMed ID: 22507876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
    J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence evaluation of 2 tablet formulations of entecavir in healthy chinese volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Jin J; Liu J; Chen J; Zhao L; Ma Z; Chen X; Huang M; Zhong G
    Arzneimittelforschung; 2012 Mar; 62(3):113-6. PubMed ID: 22282264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
    Lin Q; Zhang DZ; Zhou Z; Hu P; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):338-41. PubMed ID: 20509997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
    J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.